<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13273">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412529</url>
  </required_header>
  <id_info>
    <org_study_id>CLDT600A2407</org_study_id>
    <nct_id>NCT00412529</nct_id>
  </id_info>
  <brief_title>Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B</brief_title>
  <official_title>A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus (HBV) DNA in Adults With HBeAg-positive, Compensated Chronic Hepatitis B (CHB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study is designed to determine the early viral kinetic profile during
      treatment with telbivudine or entecavir at multiple time points over 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Mean Hepatitis B Virus (HBV) DNA Levels</measure>
    <time_frame>Baseline (day 1) to Week 12 (day 85)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean HBV DNA Level</measure>
    <time_frame>Baseline (day 1) to Weeks 2, 4, 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA.HBV DNA reductions, considered as the repeated measures, from baseline to Weeks 2, 4, 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Curve (AUC) of HBV DNA Change.</measure>
    <time_frame>From Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>In AUC efficacy analyses, all the visits from baseline to Week 12 visit (including the planned and the repeated) with a non-missing HBV DNA level were included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT) Levels</measure>
    <time_frame>From Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of Very Early Viral Kinetics: Estimation of Viral Clearance</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral kinetic parameters were estimated with a bi-phasic mathematical model:
V(t) = (1-ε)pI(t) - cV(t)
I(t) = (1- η)TV(t) - δI(t)
V serum viral load, I productively infected cells, ε efficiency factor of blocking virus production, p viral production rate, c viral clearance rate, η efficiency factor of blocking de novo infection, β de novo infection rate, T uninfected target cells, δ rate of infected cell loss. Maximum-likelihood estimation for the viral kinetic parameters entailed fitting a nonlinear differential equation system via the least-squares approach from serum HBV DNA data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of Very Early Viral Kinetics: Estimation of the Rate of Infected Cell Loss</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral kinetic parameters were estimated with a bi-phasic mathematical model:
V(t) = (1-ε)pI(t) - cV(t)
I(t) = (1- η)TV(t) - δI(t)
V serum viral load, I productively infected cells, ε efficiency factor of blocking virus production, p viral production rate, c viral clearance rate, η efficiency factor of blocking de novo infection, β de novo infection rate, T uninfected target cells, δ rate of infected cell loss. Maximum-likelihood estimation for the viral kinetic parameters entailed fitting a nonlinear differential equation system via the least-squares approach from serum HBV DNA data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of Very Early Viral Kinetics: Estimation of the Efficiency Factor of Blocking Virus Production</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral kinetic parameters were estimated with a bi-phasic mathematical model of HBV DNA by using compartments of free virus, infected cells, and uninfected target cells. The model parameter of interest was the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε). Blocking efficiency was within the range between 0 and 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Are Polymerase Chain Reaction (PCR) Negative</measure>
    <time_frame>At Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>PCR negative was considered &lt;300 copies/mL. PCR positive was considered =&gt;300 copies/mL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Telbivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
    <arm_group_label>Entecavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>Telbivudine 600 mg once daily for 12 weeks.</description>
    <arm_group_label>Telbivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18-70 years of age with documented compensated hepatitis B &quot;e&quot;
             antigen (HBeAg)-positive chronic hepatitis B

          -  Able to comply with study regimen and provide written informed consent

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Unwilling to use double barrier method of contraception

          -  Co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV) or human
             immunodeficiency virus (HIV)

          -  Received Hepatitis B therapy in the past

          -  Use of immunomodulatory therapy in past 12 months

          -  History of or symptoms of hepatic decompensation or pancreatitis

          -  Frequent or prolonged use of potentially hepatotoxic or nephrotoxic drugs

          -  Concurrent medication likely to preclude compliance with schedule of evaluations

          -  Use of other investigational drugs within 30 days of enrollment

          -  Abnormal laboratory values during screening

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holy Family Hospital_Bucheon</name>
      <address>
        <city>Bucheon,Kyunggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon Univ. Gil Medical Center Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Medical Center_Anam</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826006/?tool=pubmed</url>
    <description>Early Viral Kinetics of Telbivudine and Entecavir: Results of a 12-Week Randomized Exploratory Study with Patients with HBeAg-Positive Chronic Hepatitis B</description>
  </link>
  <results_reference>
    <citation>Suh DJ, Um SH, Herrmann E, Kim JH, Lee YS, Lee HJ, Lee MS, Lee YJ, Bao W, Lopez P, Lee HC, Avila C, Zeuzem S. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother. 2010 Mar;54(3):1242-7. doi: 10.1128/AAC.01163-09. Epub 2009 Dec 22.</citation>
    <PMID>20028815</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 23, 2015</lastchanged_date>
  <firstreceived_date>December 15, 2006</firstreceived_date>
  <firstreceived_results_date>December 2, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBeAg-positive, chronic hepatitis B</keyword>
  <keyword>telbivudine</keyword>
  <keyword>entecavir</keyword>
  <keyword>viral kinetics</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telbivudine</title>
          <description>Telbivudine 600 mg once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Entecavir</title>
          <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telbivudine</title>
          <description>Telbivudine 600 mg once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Entecavir</title>
          <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="44"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Baseline Measures based on Intention to treat population.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36.2" spread="9.62"/>
                <measurement group_id="B2" value="33.4" spread="8.82"/>
                <measurement group_id="B3" value="34.9" spread="9.25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Hepatitis B Virus (HBV) DNA Levels</title>
        <description>Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA.</description>
        <time_frame>Baseline (day 1) to Week 12 (day 85)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to Treat (ITT) population included all patients who received at least one dose of study drug and had at least one post-baseline assessment of serum HBV DNA. The randomized treatment was used in the analyses of this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Telbivudine</title>
            <description>Telbivudine 600 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Entecavir</title>
            <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Mean Hepatitis B Virus (HBV) DNA Levels</title>
            <description>Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA.</description>
            <units>log10 copies/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline (day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.290" spread="1.6477"/>
                  <measurement group_id="O2" value="9.721" spread="1.7141"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.669" spread="0.8817"/>
                  <measurement group_id="O2" value="3.194" spread="1.1729"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline to week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.621" spread="1.5610"/>
                  <measurement group_id="O2" value="-6.527" spread="1.5365"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean HBV DNA Level</title>
        <description>Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA.HBV DNA reductions, considered as the repeated measures, from baseline to Weeks 2, 4, 8.</description>
        <time_frame>Baseline (day 1) to Weeks 2, 4, 8</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to Treat (ITT) population included all patients who received at least one dose of study drug and had at least one post-baseline assessment of serum HBV DNA. The randomized treatment was used in the analyses of this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Telbivudine</title>
            <description>Telbivudine 600 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Entecavir</title>
            <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Mean HBV DNA Level</title>
            <description>Baseline HBV DNA is defined as the last pre-dose assessment of HBV DNA.HBV DNA reductions, considered as the repeated measures, from baseline to Weeks 2, 4, 8.</description>
            <units>log10 copies/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Change from Baseline to week 2 :(N=20, 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.999" spread="1.3917" lower_limit="3.04" upper_limit="4.30"/>
                  <measurement group_id="O2" value="-3.974" spread="1.3460" lower_limit="3.32" upper_limit="4.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline to week 4 : (N= 23, 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.273" spread="1.3071" lower_limit="4.55" upper_limit="5.58"/>
                  <measurement group_id="O2" value="-4.875" spread="1.5781" lower_limit="4.58" upper_limit="5.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline to week 8 : (N= 23, 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.161" spread="1.4937" lower_limit="5.23" upper_limit="6.26"/>
                  <measurement group_id="O2" value="-5.976" spread="1.5288" lower_limit="5.44" upper_limit="6.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Area Under the Curve (AUC) of HBV DNA Change.</title>
        <description>In AUC efficacy analyses, all the visits from baseline to Week 12 visit (including the planned and the repeated) with a non-missing HBV DNA level were included.</description>
        <time_frame>From Baseline to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention-to-treat (ITT) population included all patients who received at least one dose of study drug and had at least one post-baseline assessment of serum HBV DNA. The randomized treatment was used in the analyses of this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Telbivudine</title>
            <description>Telbivudine 600 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Entecavir</title>
            <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Area Under the Curve (AUC) of HBV DNA Change.</title>
            <description>In AUC efficacy analyses, all the visits from baseline to Week 12 visit (including the planned and the repeated) with a non-missing HBV DNA level were included.</description>
            <units>(log10 copies/mL) * days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-453.5" spread="103.13" lower_limit="369.5" upper_limit="462.42"/>
                  <measurement group_id="O2" value="-442.6" spread="131.30" lower_limit="395.87" upper_limit="488.79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alanine Aminotransferase (ALT) Levels</title>
        <time_frame>From Baseline to Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention to treat (ITT) population included all patients who received at least one dose of study drug and had at least one post-baseline assessment of serum HBV DNA. The randomized treatment was used in the analyses of this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Telbivudine</title>
            <description>Telbivudine 600 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Entecavir</title>
            <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Alanine Aminotransferase (ALT) Levels</title>
            <units>IU/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="163.1" spread="125.29"/>
                  <measurement group_id="O2" value="170.2" spread="152.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55.1" spread="63.92"/>
                  <measurement group_id="O2" value="54.0" spread="36.92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline to Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-108.0" spread="147.87"/>
                  <measurement group_id="O2" value="-116.3" spread="162.81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of Very Early Viral Kinetics: Estimation of Viral Clearance</title>
        <description>Viral kinetic parameters were estimated with a bi-phasic mathematical model:
V(t) = (1-ε)pI(t) – cV(t)
I(t) = (1- η)TV(t) – δI(t)
V serum viral load, I productively infected cells, ε efficiency factor of blocking virus production, p viral production rate, c viral clearance rate, η efficiency factor of blocking de novo infection, β de novo infection rate, T uninfected target cells, δ rate of infected cell loss. Maximum-likelihood estimation for the viral kinetic parameters entailed fitting a nonlinear differential equation system via the least-squares approach from serum HBV DNA data.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Telbivudine</title>
            <description>Telbivudine 600 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Entecavir</title>
            <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Characterization of Very Early Viral Kinetics: Estimation of Viral Clearance</title>
            <description>Viral kinetic parameters were estimated with a bi-phasic mathematical model:
V(t) = (1-ε)pI(t) – cV(t)
I(t) = (1- η)TV(t) – δI(t)
V serum viral load, I productively infected cells, ε efficiency factor of blocking virus production, p viral production rate, c viral clearance rate, η efficiency factor of blocking de novo infection, β de novo infection rate, T uninfected target cells, δ rate of infected cell loss. Maximum-likelihood estimation for the viral kinetic parameters entailed fitting a nonlinear differential equation system via the least-squares approach from serum HBV DNA data.</description>
            <units>clearance per day</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.809" spread="0.3904"/>
                  <measurement group_id="O2" value="1.002" spread="0.8162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of Very Early Viral Kinetics: Estimation of the Rate of Infected Cell Loss</title>
        <description>Viral kinetic parameters were estimated with a bi-phasic mathematical model:
V(t) = (1-ε)pI(t) – cV(t)
I(t) = (1- η)TV(t) – δI(t)
V serum viral load, I productively infected cells, ε efficiency factor of blocking virus production, p viral production rate, c viral clearance rate, η efficiency factor of blocking de novo infection, β de novo infection rate, T uninfected target cells, δ rate of infected cell loss. Maximum-likelihood estimation for the viral kinetic parameters entailed fitting a nonlinear differential equation system via the least-squares approach from serum HBV DNA data.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to Treat (ITT) population. The value for the rate of infected cell loss for 1 patient in telbivudine arm was not used in calculation of summary statistics for this variable as this patient showed a deviation from the biphasic pattern in viral kinetic modeling.</population>
        <group_list>
          <group group_id="O1">
            <title>Telbivudine</title>
            <description>Telbivudine 600 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Entecavir</title>
            <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Characterization of Very Early Viral Kinetics: Estimation of the Rate of Infected Cell Loss</title>
            <description>Viral kinetic parameters were estimated with a bi-phasic mathematical model:
V(t) = (1-ε)pI(t) – cV(t)
I(t) = (1- η)TV(t) – δI(t)
V serum viral load, I productively infected cells, ε efficiency factor of blocking virus production, p viral production rate, c viral clearance rate, η efficiency factor of blocking de novo infection, β de novo infection rate, T uninfected target cells, δ rate of infected cell loss. Maximum-likelihood estimation for the viral kinetic parameters entailed fitting a nonlinear differential equation system via the least-squares approach from serum HBV DNA data.</description>
            <units>infected cell loss per day</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.075" spread="0.0231"/>
                  <measurement group_id="O2" value="0.071" spread="0.0227"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of Very Early Viral Kinetics: Estimation of the Efficiency Factor of Blocking Virus Production</title>
        <description>Viral kinetic parameters were estimated with a bi-phasic mathematical model of HBV DNA by using compartments of free virus, infected cells, and uninfected target cells. The model parameter of interest was the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε). Blocking efficiency was within the range between 0 and 1.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Telbivudine</title>
            <description>Telbivudine 600 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Entecavir</title>
            <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Characterization of Very Early Viral Kinetics: Estimation of the Efficiency Factor of Blocking Virus Production</title>
            <description>Viral kinetic parameters were estimated with a bi-phasic mathematical model of HBV DNA by using compartments of free virus, infected cells, and uninfected target cells. The model parameter of interest was the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε). Blocking efficiency was within the range between 0 and 1.</description>
            <units>percentage of blocking efficiency</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.991" spread="0.0133"/>
                  <measurement group_id="O2" value="0.992" spread="0.0090"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Are Polymerase Chain Reaction (PCR) Negative</title>
        <description>PCR negative was considered &lt;300 copies/mL. PCR positive was considered =&gt;300 copies/mL.</description>
        <time_frame>At Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to Treat (ITT) population included all patients who received at least one dose of study drug and had at least one post-baseline assessment of serum HBV DNA. The randomized treatment was used in the analyses of this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Telbivudine</title>
            <description>Telbivudine 600 mg once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Entecavir</title>
            <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients Who Are Polymerase Chain Reaction (PCR) Negative</title>
            <description>PCR negative was considered &lt;300 copies/mL. PCR positive was considered =&gt;300 copies/mL.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&lt;300 copies/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 300 copies/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Safety population included all patients who received at least one dose of study drug and had at least one post-baseline safety assessment (i.e., adverse event or laboratory assessment).</desc>
      <group_list>
        <group group_id="E1">
          <title>Telbivudine</title>
          <description>Telbivudine 600 mg once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Entecavir</title>
          <description>Entecavir 0.5 mg once daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
